Thank you, Mr. Chair. That's a pleasant bonus.
I'm going to expand on Ms. Gladu's line of questioning. I was hoping she'd have more time to do this, so I'll just simply continue it.
We talked about how you identify prices that are quite above the median of the OECD countries, yet you said we are paying among the third-highest prices in the OECD.
How has this not been addressed in these places and corrective action taken, both with the rare disease ones, and again going back to insulin, and many other common drugs that we're paying much, much more for—sometimes orders of magnitude more—than other OECD countries?